Arcus' new HIF-2a data in kidney cancer hint at potential edge over Merck's Welireg, analysts say

Arcus' new HIF-2a data in kidney cancer hint at potential edge over Merck's Welireg, analysts say

Submitted by admin on October 24, 2024 - 8:27pm
Source: 
Fierce Biotech
News Tags: 
Arcus Biosciences
kidney cancer
Merck
casdatifan
Welireg
Headline: 
Arcus' new HIF-2a data in kidney cancer hint at potential edge over Merck's Welireg, analysts say
snippet: 

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give Merck’s Welireg a run for its money in kidney cancer.

Do Not Allow Advertisers to Use My Personal information